Business
Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates
SONATA-HCM anticipated to be fully enrolled mid-2026 Resubmission of NDA for ZYNQUISTA® in type 1 diabetes anticipated mid-2026 with potential for approval this year Clinical development of LX9851 initiated by Novo Nordisk Capital raise, development milestone payments, and recent $100 million loan facility reinforce strong financial position Conference call and webcast at 8:30 am ET THE WOODLANDS, Texas, May 07, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reporte
About this update from Lexicon Pharmaceuticals, Inc.
[{"type":"image","alt":"Lexicon Pharmaceuticals, Inc.","displaySize":"","headline":null,"caption":"Lexicon Pharmaceuticals, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":166,"height":50,"url":"https://media.zenfs.com/en/globenewswire.com/4d6e4fe42ab02751f185e7d242d7f8e8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/cpcXdPITJqolET8.Vg1gcg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTYz/https://media.zenfs.com/en/globenewswire.com/4d6e4fe42ab02751f185e7d242d7f8e8","width":166,"height":50},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/cpcXdPITJqolET8.Vg1gcg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTYz/https://media.zenfs.com/en/globenewswire.com/4d6e4fe42ab02751f185e7d242d7f8e8","width":166,"height":50}},"lazy":false},{"type":"text","content":"SONATA-HCM anticipated to be fully enrolled mid-2026 ","length":52,"tagName":"p"},{"type":"text","content":"Resubmission of NDA for ZYNQUISTA® in type 1 diabetes anticipated mid-2026 with potential for approval this year","length":112,"tagName":"p"},{"type":"text","content":"Clinical development of LX9851 initiated by Novo Nordisk ","length":56,"tagName":"p"},{"type":"text","content":"Capital raise, development milestone payments, and recent $100 million loan facility reinforce strong financial position ","length":121,"tagName":"p"},{"type":"text","content":"Conference call and webcast at 8:30 am ET","length":41,"tagName":"p"},{"type":"text","content":"THE WOODLANDS, Texas, May 07, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended March 31, 2026, and provided an update on key corporate milestones and accomplishments.","length":248,"tagName":"p"},{"type":"text","content":"“We have been intently focused on progressing our late and early-stage development pipeline in cardiometabolism and we are now well positioned to achieve several pivotal milestones as a result of those efforts,” said Mike Exton, Ph.D., Lexicon’s chief executive officer and director. “Over the next 12 months, those events potentially include the announcement of topline data from our ongoing registrational trial of sotagliflozin in hypertrophic cardiomyopathy, U.S. regulatory approval of ZYNQUISTA as the first adjunct to insulin for glycemic management in people with type 1 diabetes and the completion of initial Phase 1 development ...